Navigation Links
STAAR Surgical Reports 33% Third Quarter Revenue Growth
Date:10/28/2008

Proceeds from sale of property,

plant and equipment 100 12

Dividend received from joint

venture - 117

Net change in other assets 149 6

Net cash provided by (used

in) investing activities 1,662 (233)

Cash flows from financing activities:

Proceeds from notes payable - 4,000

Repayments of notes payable - (4,000)

Borrowings under lines of credit 3,760 1,812

Repayments of lines of credit (1,880) (3,610)

Repayment of capital lease lines

of credit (762) (444)

Net proceeds from the public sale

of equity securities - 16,613

Proceeds from the exercise of

stock options 40 584

Net cash provided by

financing activities 1,158 14,955

Effect of exchange rate changes on

cash and cash equivalents 219 229

(Decrease) increase in cash and cash

equivalents (4,198) 6,438

Cash and cash equivalents, at

beginning of the period 10,895 7,758

Cash and cash equivalents, at end of

the period $6,697 $14,196

STAAR Surgical Company

GAAP Reconciliation Table

26-Sep-08

Q3 2008

Statement of Operations As Reported Japan Ex-Japan

Sales
'/>"/>

SOURCE STAAR Surgical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. STAAR Surgical to Present at the Noble Financial Equity Conference
2. STAAR Surgicals Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification
3. STAAR Surgicals LASIK Alternative Expands U.S. Market Gains
4. STAAR Surgical Reports Solid First Quarter Progress
5. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
6. STAAR Surgical Plans Major Presence at ASCRS
7. STAAR Surgical Reports Fourth Quarter and Year End Results
8. STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show
9. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
10. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
11. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Company's Award-Winning Sound Enhancement Technology Proven to Provide Superior Performance Over Other Technologies; Patent Will Enhance Able Planet, LINX AUDIO Brands 2Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 2Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 3Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 4Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 5Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:Evolutionary phenomenon in mice may explain human infertility 2Health News:A Little Regular Exercise Extends Men's Lives 2Health News:A Little Regular Exercise Extends Men's Lives 3Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2
Breaking Medicine Technology:AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 1Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 2Uroplasty Reports First Fiscal Quarter Results 53547 1Uroplasty Reports First Fiscal Quarter Results 53547 2Uroplasty Reports First Fiscal Quarter Results 53547 3Uroplasty Reports First Fiscal Quarter Results 53547 4Uroplasty Reports First Fiscal Quarter Results 53547 5Uroplasty Reports First Fiscal Quarter Results 53547 6Uroplasty Reports First Fiscal Quarter Results 53547 7Uroplasty Reports First Fiscal Quarter Results 53547 8Uroplasty Reports First Fiscal Quarter Results 53547 9Uroplasty Reports First Fiscal Quarter Results 53547 10Uroplasty Reports First Fiscal Quarter Results 53547 11Uroplasty Reports First Fiscal Quarter Results 53547 12Uroplasty Reports First Fiscal Quarter Results 53547 13Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 1Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 2Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 3Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 4Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 5Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 6Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 7Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 8Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 9Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 10